Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06958796 · ClinicalTrials.gov registry record · Phase 4
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
A Phase 4 study of Kidney Transplant; Complications and Liver Transplant, Complications, sponsored by Camille N. Kotton, MD.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT06958796: Recruiting Phase 4 study of Kidney Transplant; Complications and Liver Transplant, Complications, sponsored by Camille N. Kotton, MD.
NCT06958796 is a Phase 4 study of Kidney Transplant; Complications and Liver Transplant, Complications that is actively recruiting participants, run by Camille N. Kotton, MD. The registered enrollment target is 80 participants, below the 118-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (32% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06958796, a Phase 4 study of Kidney Transplant; Complications and Liver Transplant, Complications, is actively recruiting participants, sponsored by Camille N. Kotton, MD.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.
Primary Outcome
Comparison between treatment groups of number of participants with a blood CMV viral load \>1000 IU/ml at any point during the treatment phase through end of study
Conditions Studied
Interventions
- DRUG Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-11-27 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 4 |
What NCT06958796 shows while recruiting
NCT06958796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 118-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (32% lower).
The record links to 5 conditions, with Kidney Transplant; Complications appearing as the primary indexed condition, and to 1 intervention - of which Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months is the first listed.
NCT06958796 reports a single indexed study location in Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT06958796 about?
NCT06958796 is a clinical study titled "Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)". This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver and/or kidney transplant.
What is the current status of trial NCT06958796?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2025-11-27. Estimated completion is 2028-05-31.
What conditions does trial NCT06958796 study?
This clinical trial studies the following conditions: Kidney Transplant; Complications, Liver Transplant, Complications, Cytomegalovirus, Organ Transplant, Simultaneous Liver-Kidney Transplantation; Complications.
What interventions are being tested in trial NCT06958796?
The interventions under investigation include: Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months (DRUG).
Who is sponsoring clinical trial NCT06958796?
This trial is sponsored by Camille N. Kotton, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06958796 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant; Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06958796's enrollment target sits among peer trials
80 10th of 19 higher than 8 of 19 other Kidney Transplant; Complications trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant; Complications trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants
ACTIVE NOT RECRUITING · Phase 4
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery
COMPLETED · Phase 4
-
Immune Registry for BK in Kidney Transplant Recipients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI